TRASTUZUMAB
Metastatic Malignant Neoplasm to Brain
Kadmon Corporation, LLCmonoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Metastatic Malignant Neoplasm to Brain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
4-demethyl-4-cholestryloxycarbonylpenclomedine DEKK-TEC, Inc. | Phase 2 | B |
Cyclophosphamide Massachusetts General Hospital | Phase 2 | CCC |
Palbociclib Massachusetts General Hospital | Phase 2 | CCC |
Epirubicin Massachusetts General Hospital | Phase 2 | CCC |
Pembrolizumab Massachusetts General Hospital | Phase 2 | CCC |
Tesevatinib Kadmon Corporation, LLC | Phase 1/2 | CCC |
(+)-VINCRISTINE Centre Francois Baclesse | Phase 1 | CC |
Irinotecan Centre Francois Baclesse | Phase 1 | CC |
Same molecule, other indications
TRASTUZUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →